[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100382184":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":13,"overallOfficials":13,"centralContacts":31,"locations":41,"responsibleParty":60,"collaborators":13,"id":62,"slug":13,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":13,"studyType":75,"phases":13,"briefSummary":76,"conditions":77,"keywords":13,"overallStatus":44,"whyStopped":13,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Göteborg University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Inflammatory status","The inflammatory status, defined as CRP levels and ability to respond to pro-resolving therapeutics, will be studied in all 6 groups","2027",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","Subjects are recruited either via open adds of after having indicated in previous study registers that they are interested in participating as volunteers in future studies.",[19,21,23,25,27,29],{"label":20,"type":13,"description":13,"interventionNames":13},"Lean and metabolically healthy",{"label":22,"type":13,"description":13,"interventionNames":13},"Lean and metabolically unhealthy",{"label":24,"type":13,"description":13,"interventionNames":13},"Overweight and metabolically healthy",{"label":26,"type":13,"description":13,"interventionNames":13},"Overweight and metabolically unhealthy",{"label":28,"type":13,"description":13,"interventionNames":13},"Obese and metabolically healthy",{"label":30,"type":13,"description":13,"interventionNames":13},"Obese and metabolically unhealthy",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Emma Börgeson, PhD","CONTACT","+46313423833","emma.borgeson@wlab.gu.se",{"name":38,"role":34,"phone":39,"phoneExt":13,"email":40},"Per-Anders Jansson, MD, PhD","+46313420000","Per-Anders.Jansson@wlab.gu.se",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Gothenburg university","RECRUITING","Gothenburg","Västra Götaland County","41669","Sweden","SE",{"type":51,"coordinates":52},"Point",[53,54],11.96679,57.70716,{"lat":54,"lon":53},[57,58],{"name":33,"role":34,"phone":39,"phoneExt":13,"email":36},{"name":59,"role":34,"phone":39,"phoneExt":13,"email":40},"Per-Anders Jansson, PhD, MD",{"type":61,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100382184",false,"NCT04256330","Cardiometabolic Health and Inflammatory Resolution","Cardiometabolic Health and Inflammatory Resolution (Kardiometabol hälsa Och Inflammatorisk Resolution)","REX","Inclusion Criteria:\n\n* Informed signed consent has been obtained from the volunteer.\n* The volunteer has a BMI greater than 18.5 kg\u002Fm2\n\nExclusion Criteria:\n\n* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.\n* An MD determines that the individual is on too many medications to participate\n* The individual takes a medication that is approved by the MD, but he\u002Fshe is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.\n* The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)\n* The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.\n* The individual has some form of chronic inflammation.\n* The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).\n* The individual uses immunosuppressive drugs (eg, methotrexate).\n* The individual regularly consumes fish oils (omega 3).\n* The individual has significant gastrointestinal problems.\n* The individual smokes or uses chewing tobacco.\n* The individual has been drinking alcohol two days before the study visit.\n* The individual has tattoos or body piercings on the forearms and \u002F or the stomach that can affect the examination.\n* The individual does not follow instructions given in the research study.","ALL","18 Years","65 Years",{"count":73,"type":74},200,"ESTIMATED","OBSERVATIONAL","The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg\u002Fm2), overweight (25.0-29.9 kg\u002Fm2) or obese (\\>30.0 kg\u002Fm2).",[78],"Volunteers","2025-05-05",{"date":81,"type":82},"2025-05-08","ACTUAL",{"date":84,"type":82},"2020-01-23",{"date":86,"type":74},"2027-09-01",{"name":5,"class":6},1]